Monopar Therapeutics — Director's Dealing 2024

Oct 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-09-30

Reporting Person: Robinson Chandler (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-30	Common Stock	M	4895	—	Acquired	58080	Direct
2024-09-30	Common Stock	F	1918	$6.74	Disposed	56162	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-30	Restricted Stock Units	$	M	4895	Disposed		Common Stock (4895)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	822255	Indirect
Common Stock	33334	Indirect

Footnotes

F1: Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split

F2: Represents shares acquired on vesting and settlement of restricted stock units.

F3: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

F4: This is based upon the 822,255 shares of Monopar common stock that Tactic Pharma LLC indirectly controls through TacticGem LLC. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 822,255 shares. Dr. Robinson disclaims beneficial ownership of the 822,255 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.

F5: This is based upon the 33,334 shares of Monopar common stock that Tactic Pharma LLC directly owns. As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 33,334 shares. Dr. Robinson disclaims beneficial ownership of the 33,334 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.

F6: On January 26, 2021, the reporting person was granted 12,612 restricted stock units, vesting 6/48ths (1,577 shares) on June 30, 2021, and 3/48ths (788 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F7: On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F8: On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.